Last reviewed · How we verify
Cyclopentolate+tropicamide+phenylephrine — Competitive Intelligence Brief
marketed
Anticholinergic + sympathomimetic combination
Muscarinic acetylcholine receptors (M1-M5); alpha-1 adrenergic receptor
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
Cyclopentolate+tropicamide+phenylephrine (Cyclopentolate+tropicamide+phenylephrine) — Pontificia Universidad Catolica de Chile. This combination of three anticholinergic and sympathomimetic agents dilates the pupil and paralyzes accommodation for ophthalmic examination.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cyclopentolate+tropicamide+phenylephrine TARGET | Cyclopentolate+tropicamide+phenylephrine | Pontificia Universidad Catolica de Chile | marketed | Anticholinergic + sympathomimetic combination | Muscarinic acetylcholine receptors (M1-M5); alpha-1 adrenergic receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Anticholinergic + sympathomimetic combination class)
- Pontificia Universidad Catolica de Chile · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cyclopentolate+tropicamide+phenylephrine CI watch — RSS
- Cyclopentolate+tropicamide+phenylephrine CI watch — Atom
- Cyclopentolate+tropicamide+phenylephrine CI watch — JSON
- Cyclopentolate+tropicamide+phenylephrine alone — RSS
- Whole Anticholinergic + sympathomimetic combination class — RSS
Cite this brief
Drug Landscape (2026). Cyclopentolate+tropicamide+phenylephrine — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclopentolate-tropicamide-phenylephrine. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab